Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013

View More View Less
  • 1 From Dana-Farber/Brigham and Women’s Cancer Center; Moffitt Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Michigan Comprehensive Cancer Center; Fox Chase Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; UNMC Eppley Cancer Center at The Nebraska Medical Center; Duke Cancer Institute; Roswell Park Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Vanderbilt-Ingram Cancer Center; City of Hope Comprehensive Cancer Center; Stanford Cancer Institute; University of Alabama at Birmingham Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; The University of Texas MD Anderson Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Huntsman Cancer Institute at the University of Utah; Memorial Sloan-Kettering Cancer Center; St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute; and National Comprehensive Cancer Network.
Restricted access

These NCCN Guidelines Insights highlight the important updates/changes specific to the management of Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma. These include the addition of regimens containing novel agents as primary and salvage therapy options, inclusion of the updated summary of response categories and criteria from the sixth international workshop on Waldenström’s Macroglobulinemia, and a section on management of peripheral neuropathy in the accompanying discussion.

  • 1

    Owen RG, Treon SP, Al-Katib A. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 2003;30:110115.

    • Search Google Scholar
    • Export Citation
  • 2

    Harris NL, Jaffe ES, Diebold J. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:38353849.

    • Search Google Scholar
    • Export Citation
  • 3

    Swerdlow SH, Berger F, Pileri SA. Lymphoplasmacytic lymphoma. In: Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: IARC Press; 2008:194.

    • Search Google Scholar
    • Export Citation
  • 4

    Sekhar J, Sanfilippo K, Zhang Q. Waldenstrom macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005. Leuk Lymphoma 2012;53:16251626.

    • Search Google Scholar
    • Export Citation
  • 5

    Fonseca R, Hayman S. Waldenstrom macroglobulinaemia. Br J Haematol 2007;138:700720.

  • 6

    Kyle RA, Treon SP, Alexanian R. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 2003;30:116120.

    • Search Google Scholar
    • Export Citation
  • 7

    Treon SP. How I treat Waldenstrom macroglobulinemia. Blood 2009;114:23752385.

  • 8

    Chen CI, Kouroukis CT, White D. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:15701575.

    • Search Google Scholar
    • Export Citation
  • 9

    Ghobrial IM, Xie W, Padmanabhan S. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemia. Am J Hematol 2010;85:670674.

    • Search Google Scholar
    • Export Citation
  • 10

    Treon SP, Ioakimidis L, Soumerai JD. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009;27:38303835.

    • Search Google Scholar
    • Export Citation
  • 11

    Chen C, Kouroukis CT, White D. Bortezomib in relapsed or refractory Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma 2009;9:7476.

  • 12

    Rummel MJ, von Gruenhagen U, Niederle N. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with Waldenstrom’s macroglobulinemia: first interim results of a randomized phase III study of the Study Group Indolent Lymphomas (StiL) [abstract]. Presented at the 5th International Workshop on Waldenstrom’s macroglobulinemia; October 15–18, 2008; Stockholm, Sweden. Abstract 139.

    • Search Google Scholar
    • Export Citation
  • 13

    Treon SP, Hanzis CA, Ioakimidis LI. Clinical characteristics and treatment outcome of disease-related peripheral neuropathy in Waldenstrom’s macroglobulinemia (WM) [abstract]. J Clin Oncol 2010;28(15 Suppl):Abstract 8114.

    • Search Google Scholar
    • Export Citation
  • 14

    Benedetti L, Briani C, Grandis M. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst 2007;12:102107.

    • Search Google Scholar
    • Export Citation
  • 15

    Dalakas MC, Rakocevic G, Salajegheh M. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009;65:286293.

    • Search Google Scholar
    • Export Citation
  • 16

    Pestronk A, Florence J, Miller T. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003;74:485489.

    • Search Google Scholar
    • Export Citation
  • 17

    Treon SP, Gertz MA, Dimopoulos M. Update on treatment recommendations from the Third International Workshop on Waldenstrom’s macroglobulinemia. Blood 2006;107:34423446.

    • Search Google Scholar
    • Export Citation
  • 18

    Dimopoulos MA, Gertz MA, Kastritis E. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia. J Clin Oncol 2009;27:120126.

    • Search Google Scholar
    • Export Citation
  • 19

    Ghobrial IM, Fonseca R, Greipp PR. Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 2004;101:25932598.

    • Search Google Scholar
    • Export Citation
  • 20

    Treon SP, Branagan AR, Hunter Z. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom’s macroglobulinemia. Ann Oncol 2004;15:14811483.

    • Search Google Scholar
    • Export Citation
  • 21

    Treon SP, Hunter ZR, Matous J. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom’s macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007;13:33203325.

    • Search Google Scholar
    • Export Citation
  • 22

    Strauss SJ, Maharaj L, Hoare S. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006;24:21052112.

    • Search Google Scholar
    • Export Citation
  • 23

    Treon S, Tripsas C, Ioakimidis L. Prospective, multicenter study of the mTOR inhibitor everolimus (RAD001) as primary therapy in Waldenstrom’s macroglobulinemia [abstract]. Presented at the 53rd ASH Annual Meeting and Exposition; December 10–13, 2011; San Diego, California. Abstract 2951.

    • Search Google Scholar
    • Export Citation
  • 24

    Varghese AM, Rawstron AC, Ashcroft AJ. Assessment of bone marrow response in Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma 2009;9:5355.

    • Search Google Scholar
    • Export Citation
  • 25

    Treon SP, Merlini G, Morra E. Report from the Sixth International Workshop on Waldenstrom’s Macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11:6873.

    • Search Google Scholar
    • Export Citation
  • 26

    Agathocleous A, Rohatiner A, Rule S. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia. Br J Haematol 2010;151:346353.

    • Search Google Scholar
    • Export Citation
  • 27

    Ghobrial IM, Matous J, Padmanabhan S. Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia [abstract]. J Clin Oncol 2009;27(15 Suppl):Abstract 8535.

    • Search Google Scholar
    • Export Citation
  • 28

    Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC. Treatment of relapsed or refractory Waldenstrom’s macroglobulinemia with bortezomib. Haematologica 2005;90:16551658.

    • Search Google Scholar
    • Export Citation
  • 29

    Ghobrial IM, Hong F, Padmanabhan S. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:14221428.

    • Search Google Scholar
    • Export Citation
  • 30

    Treon SP, Hanzis C, Tripsas C. Bendamustine therapy in patients with relapsed or refractory Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11:133135.

    • Search Google Scholar
    • Export Citation
  • 31

    Ghobrial IM, Gertz MA, LaPlant B. A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory waldenstrom’s macroglobulinemia [abstract]. Blood 2009;114:Abstract 587.

    • Search Google Scholar
    • Export Citation
  • 32

    Furman RR, Eradat H, Switzky JC. A phase II trial of ofatumumab in subjects with Waldenstrom’s macroglobulinemia [abstract]. Blood 2010;116:Abstract 1795.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 471 313 21
PDF Downloads 149 90 8
EPUB Downloads 0 0 0